The most rigorous meta-analysis yet of CBD for nerve pain concludes the evidence is thin, even as a separate full-spectrum anxiety trial posts encouraging results.
A new Cochrane Review published this spring found no clear evidence that CBD-dominant medicines produce meaningful relief from neuropathic pain. The analysis pooled 21 randomized controlled trials covering 2,187 participants, making it the largest and most methodologically demanding look at the question to date. An updated systematic review in the Annals of Internal Medicine, covering 25 trials, reached a similar conclusion: products with low THC-to-CBD ratios did not reliably improve pain outcomes.
The findings complicate a marketing narrative that has defined the CBD category since its post-2018 consumer boom. Brands have leaned on early open-label studies and anecdotal reports to position CBD as a pain-management option. The Cochrane team, using the GRADE framework, rated the pain evidence as low to very low certainty across the studies they reviewed.
What the Reviewers Actually Found
The Cochrane authors separated pain outcomes by condition. Diabetic peripheral neuropathy, post-herpetic neuralgia, and chemotherapy-induced neuropathy each showed small effect sizes that did not reach statistical significance once adjusted for trial quality and publication bias. Average daily doses in the pooled trials ranged from 20 milligrams to 800 milligrams, with most studies clustering near 25 to 50 milligrams per day.
“We cannot say from the available trials that CBD is doing nothing for these patients,” the Cochrane team wrote. “We can say that the current evidence does not support routine clinical use, and that better-designed studies with consistent dosing and end points are needed.”
Adverse events were generally mild. Sedation, dry mouth, and transient liver-enzyme elevations appeared more often in the CBD arms than in placebo arms. Serious adverse events remained rare.
The Anxiety Picture Looks Different
A separate open-label pilot published in Biomedicines reported improvement on anxiety, mood, sleep quality, and executive function after four weeks of treatment with a full-spectrum, low-THC, high-CBD product at 30 milligrams of CBD per day. Participants with moderate-to-severe anxiety at baseline showed statistically significant movement on Beck Anxiety Inventory scores.
The anxiety trial is small. It enrolled 42 participants and lacked a blinded control arm. The authors urged caution, noting that placebo response in anxiety trials runs high. Still, the signal is directionally consistent with prior clinical work.
Menstrual Pain and TMD
Two additional 2026 studies suggest CBD may perform better on localized or musculoskeletal pain than on nerve pain. A vaginally administered CBD suppository trial reported reductions in menstrual and pelvic pain symptoms. A separate study in adults with chronic temporomandibular disorder found that a balanced THC-to-CBD preparation cut functional pain by roughly 90 percent and improved jaw mobility.
Researchers caution against reading across categories. Pain has many mechanisms, and the endocannabinoid system engages differently with each. A signal in menstrual pain does not validate a claim for diabetic neuropathy, and vice versa.
What This Means for Brands
Regulatory risk moves with the evidence base. The FDA’s new Medicare CBD pilot limits claims language and requires batch-specific certificates of analysis, but the agency has not approved any consumer CBD product for a specific medical condition. Marketing copy that leaned on pain relief should expect closer enforcement scrutiny after the Cochrane publication, according to FDA compliance attorneys.
Several brands have already edited their product pages. Charlotte’s Web removed references to nerve pain from its senior-focused product descriptions in March. Medterra shifted its mobility-line copy toward “everyday discomfort” rather than clinical pain claims. Smaller brands that rely on influencer content face the hardest adjustment, since paid creators often use clinical vocabulary regulators view as medical claims.
The Research Agenda
The Cochrane authors identified three study-design priorities. They want trials that standardize CBD product composition, including minor cannabinoid and terpene content. They want consistent pain end points that reflect patient-important outcomes rather than laboratory measures. And they want adequately powered trials with at least 200 participants per arm.
Funding remains a bottleneck. Federal cannabinoid research dollars from NIH and VA programs remain modest, and industry-funded trials carry the familiar bias-risk discount. Publicly traded cannabinoid companies funded roughly $42 million in clinical research in 2025, a fraction of what a single mid-size pharmaceutical company spends on one indication.
Clinical Implications Now
For clinicians, the review strengthens the case for treating CBD as a low-risk adjunct rather than a primary therapy for nerve pain. Patients who find subjective benefit at low doses may continue safely, but prescribing guidelines are unlikely to formally include CBD for neuropathic pain on the basis of current evidence.
For patients, the takeaway is to manage expectations and keep track of outcomes. Over-the-counter CBD costs add up. Before committing to a months-long trial, patients can benefit from a written treatment plan with measurable goals.
For more on what quality testing looks like on a bottle, see SafeCBD.com’s clinical-trial reading guide. For product research that aligns with the evidence, see the CBDProducts.com evidence-backed guide. For veterinary research parallels in pet CBD, see our CBDPet.com coverage of recent pet pain studies.
—
These statements have not been evaluated by the Food and Drug Administration. CBD products are not intended to diagnose, treat, cure, or prevent any disease.